Ajinomoto Bio-Pharma Services
https://ajibio-pharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ajinomoto Bio-Pharma Services
Japan Makes Renewed Policy Efforts To Fill 'Drug Gap'
Japan has announced several new measures to tackle the lack of rare disease and other therapeutics in the domestic market, with the country's main industry association also issuing the first common national informed consent form in a bid to lighten the “huge workload” on trial site staff.
Ajinomoto Builds Gene Therapy CDMO Capabilities Through $554m Forge Acquisition
With an ambitious growth plan for its CDMO operations, Ajinomoto is planning to complete the acquisition of Forge Biologics Holdings by December, adding the US-based firm’s capabilities in gene therapy services.
Regeneron Targets Vulnerable Populations In COVID-19 Pact With BARDA
The company is developing a next-generation antibody for prevention of COVID-19 that targets highly conserved regions of the SARS-CoV-2 virus and thus may be able to overcome resistance.
AbbVie’s Aquipta & GSK’s Jesduvroq Move Closer To EU Market
AbbVie’s migraine prophylactic and GSK’s treatment for anemia associated with chronic kidney disease were both recommended for pan-EU marketing approval by the European Medicines Agency this week.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
- Contract Manufacturing Organization
- Other Names / Subsidiaries
-
- Althea Technologies, Inc.
- Ajinomoto Pharmaceuticals Co., Ltd.
- EA Pharma Co., Ltd.
- GeneDesign
- OmniChem
- Granules OmniChem Private Limited
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice